Samsung Biologics Reports 35% Surge in Q1 Operating Profit

Samsung Biologics' operating profit for the first quarter of this year significantly increased by 35% year-on-year to 580.8 billion won, driven by high operational rates across its Plants 1-4.

The company anticipates annual revenue growth of 15-20% based on its stable production capacity and plans to re-announce its forecast once the performance of its U.S. Rockville plant is reflected.

The company's financial status is also solid, with a debt-to-equity ratio of 51.4% as of the end of the first quarter.